Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?

Immunotherapy

Volumn 6, Issue 10, 2014, Pages 1017-1020

  Zheng, Lei ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; IPILIMUMAB; PEMBROLIZUMAB; SIPULEUCEL T; CANCER VACCINE;

ADAPTIVE IMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PROCEDURES;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 84913612431     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.87     Document Type: Review

References (21)

1. Hodi FS, O'Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (8), 711-723 (2010).
2. Brahmer JR, Tykodi SS, Chow LQ. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (26), 2455-2465 (2012).
3. Topalian SL, Hodi FS, Brahmer JR. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (26), 2443-2454 (2012).
4. Hamid O, Robert C, Daud A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2), 134-144 (2013).
5. Kantoff PW, Higano CS, Shore ND. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (5), 411-422 (2010).
6. Taube JM, Klein AP, Brahmer JR. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (19), 5064-5074 2014).
7. Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144 (6), 1230-1240 (2013).
8. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67 (19), 9518-9527 (2007).
9. Beatty GL, Chiorean EG, Fishman MP. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (6024), 1612-1616 (2011).
10. Jaffee EM, Hruban RH, Biedrzycki B. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. 19 (1), 145-156 (2001).
11. Laheru D, Lutz E, Burke J. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14 (5), 1455-1463 (2008).
12. Lutz E, Yeo CJ, Lillemoe KD. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253 (2), 328-335 (2011).
13. Le DT, Lutz E, Uram JN. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36 (7), 382-389 (2013).
14. Thomas AM, Santarsiero LM, Lutz ER. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200 (3), 297-306 (2004).
15. Lutz ER, Wu AA, Bigelow E. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2 (7), 616-631 (2014).
16. Goc J, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2 (12), e26836 (2013).
17. Taube JM, Anders RA, Young GD. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4 (127), 127ra137 (2012).
18. Soares KC, Rucki AA, Wu A. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J. Immunotherapy (2014) (. In Press).
19. Wrangle J, Wang W, Koch A. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4 (11), 2067-2079 (2014).
20. Li H, Chiappinelli KB, Guzzetta AA. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5 (3), 587-598 (2014).
21. Wolchok JD, Kluger H, Callahan MK. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2), 122-133 (2013).